Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018133 (graft-versus-host disease)
 18,032 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Fifty-eight samples of bone marrow (31), whole peripheral blood (8) and separated fractions of circulating mononuclear (11) and polymorphonuclear (8) cells from 18 male patients, transplanted for hematological diseases from related (14) or unrelated (4) female donors were analyzed for chimerism at subsequent intervals (range, 1-72 months) following bone marrow transplantation, by means of PCR amplification of the Y-chromosome-specific DYS14 sequence, revealed by a radiolabelled hybridization probe (dot blot technique, 0.01% sensitivity). Detection of male cells was positive in all but two of 52 samples collected within the third year after transplantation and negative in six samples collected from three patients after the third year. In the first year after transplantation, mixed chimerism was found in all patients, apparently with no correlation with graft-versus-host disease. Comparable results were found in fractions of mononuclear and polymorphonuclear cells, when analyzed separately. The persistence of very low levels of recipient cells in patients in continuous complete remission until the third year after transplantation, suggests the persistence of normal host hemopoiesis for a long period of time after the so-called myeloablative regimen. The progressive negativization, occurring in our patients between the second and the fourth year after transplantation, could signify the disappearance of residual host hemopoiesis or its decrease to below the detection level of this highly sensitive method.
 ...
PMID:Long-term persistence of hemopoietic chimerism following sex-mismatched bone marrow transplantation. 942 77

Male DNA, of presumed fetal origin, can be detected in the maternal circulation decades after delivery and is referred to as fetal microchimerism (FM). We previously found quantitatively greater FM in the circulation of women with the autoimmune disease scleroderma (SSc) than of healthy women. However, it is unknown whether this difference is due to intact circulating cells or free DNA released from breakdown in disease-affected tissues. To distinguish the origin of FM, we developed a real-time quantitative polymerase chain reaction (PCR) assay for the Y-chromosome-specific sequence DYS14, and tested 114 women in peripheral blood mononuclear cells (PBMCs) and/or plasma. Fifty-seven controls and 57 SSc patients were studied, 48 and 43 of whom, respectively, had given birth to at least one son. Circulating FM was quantitatively greater in PBMCs from SSc patients (n = 39; range, 0.0-12.5 male genome-equivalent cells per million maternal cells), compared with healthy women (n = 39; range, 0.0-4.4; P =.03). In contrast, there was no difference between patients (n = 25) and controls (n = 22) in plasma, and no evidence of free DNA. FM was enriched among T lymphocytes compared with PBMCs (P =.01) in controls (n = 14), but not in SSc patients (n = 14); the latter finding was most likely due to immunosuppressive medications. In conclusion, this real-time quantitative assay showed that quantitative differences in the circulation of women with SSc are due to cells and not to free DNA. As FM was not uncommon in healthy women, including among T cells, and because graft-versus-host disease has similarities to SSc, these results also suggest that FM merits investigation in pheresis products used for stem cell transplantation.
 ...
PMID:Male microchimerism in healthy women and women with scleroderma: cells or circulating DNA? A quantitative answer. 1235 94

Increased risk of graft-versus-host disease (GVHD) has been described in recipients of hematopoietic stem cell transplantations when the donor is a parous woman. Cells from prior pregnancies are now known to persist in women and could contribute to GVHD. We asked whether male DNA (presumed fetal microchimerism) is present in apheresis products of female donors. A total of 50 samples were studied by using real-time quantitative polymerase chain reaction (PCR) for the Y chromosome-specific sequence DYS14. Among 29 growth factor-mobilized peripheral blood mononuclear cell (G-PBMC) products, 34% were positive for male DNA. Quantitative results, expressed as DNA genome equivalent of male cells per million host cells (gEq/mil), ranged from 0 to 35 gEq/mil. Among 21 CD34-enriched cell fractions, 48% were positive with a range of 0 to 357 gEq/mil. In summary, male DNA was frequently detected in G-PBMC and CD34-enriched products from female donors. Whether fetal microchimerism contributes to GVHD merits further investigation.
 ...
PMID:Male DNA in female donor apheresis and CD34-enriched products. 1286 96